THERAPY DOSSIER · th-0575dadd9dd5

Tetramethylpyrazine

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 3

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT05942352 ↗PHASE4unknown

Clinical Study of Ligustrazine in Treating Alcohol Addiction

Alcohol Abuse · Arteriosclerosis

Enrolment: 400 · Results not recorded

NCT04667013 ↗PHASE1not yet recruiting

Bridged Phase 1 study of multiple doses of tetramethylpyrazine nitrone (TBN) tablet in healthy subjects

Healthy

Enrolment: 16 · Results not recorded

NCT07530016 ↗NAnot yet recruiting

Ligustrazine-tranexamic acid-aloe polysaccharide composite gel for stable melasma

Melasma

Enrolment: 10 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 23446291 ↗2013Reported benefit

Tetramethylpyrazine prevents contrast-induced nephropathy by inhibiting p38 MAPK and FoxO1 signaling pathways.

RatChemical/toxinSprague-DawleyMale

Model: Contrast-induced nephropathy (acute kidney injury) induced by contrast medium

Tetramethylpyrazine significantly attenuated the renal dysfunction and renal tubular cell apoptosis caused by contrast medium. Mechanistically it decreased phospho-p38 MAPK, attenuated the rise in FoxO1 mRNA and nuclear protein, inhibited inducible nitric oxide synthase and Bax, and upregulated Bcl…

Extraction: extract · Supplied extraction confidence: 0.65. Machine-extracted fields require source verification.

Loading the evidence…